AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32502505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (PORT) for grade II IEPN
Number of subjects: 172
Study 32502505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (PORT) for grade III IEPN
Number of subjects: 172
Study 32502505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (PORT) for all grade II-III IEPNs
Number of subjects: 172
Study 35964896 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 19373
Study 35964896 — intervention group
Group type: COMPARATOR
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 19373
Study 35964896 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted screening
Number of subjects: 19373
Study 33496536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative freehand bilateral ESPB with a 20-mL mixture solution of 0.25% bupivacaine and 1.0% lidocaine
Number of subjects: 56
Study 33496536 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline injection (Control)
Number of subjects: 56
Study 32687091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (IL) 20% infusion at 2 ml/kg, 30 min prior to revascularization
Number of subjects: 30
Study 32687091 — intervention group
Group type: COMPARATOR
Intervention: Control group received normal saline infusion
Number of subjects: 30
Study 83151875 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic-Aid diet (20-g Casein/30-g Hepatic-Aid per day)
Number of subjects: 4
Study 83151875 — intervention group
Group type: COMPARATOR
Intervention: Casein diet (50-g Casein per day)
Number of subjects: 4
Study 83151875 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic-Aid diet
Number of subjects: 4
Study 34118248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d)
Number of subjects: 174
Study 34118248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 33548749 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue massage (DTM) applied by midwife, twice at the 10th and 22nd hour after cesarean.
Number of subjects: 0
Study 33548749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no applications performed).
Number of subjects: 0
Study 33548749 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue massage (DTM) applied by midwife.
Number of subjects: 0
Study 34959975 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg Folic Acid
Number of subjects: 1060
Study 34959975 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg Folic Acid
Number of subjects: 1060
Study 35213275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayes factor method
Number of subjects: 0
Study 35213275 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilizing historical data
Number of subjects: 0
Study 35213275 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous test
Number of subjects: 0
Study 35213275 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior variance criterion
Number of subjects: 0
Study 35213275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayes factor criterion
Number of subjects: 0
Study 32601955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic capsules (Bacillus coagulans Unique IS2, Lactobacillus rhamnosus UBLR58, Bifidobacterium lactis UBBLa70, Lactobacillus plantarum UBLP40 each of 2 billion CFU; Bifidobacterium breve UBBr01, Bifidobacterium infantis UBBI01 each of 1 billion CFU) with glutamine (250 mg) taken twice a day for 28 days
Number of subjects: 80
Study 32601955 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules taken twice a day for 28 days
Number of subjects: 80
Study 34348666 — intervention group
Group type: EXPERIMENTAL
Intervention: LTV-h.PEEP ventilation (TV of 6 ml/IBW and PEEP of 10 cm H2O)
Number of subjects: 24
Study 34348666 — intervention group
Group type: COMPARATOR
Intervention: HTV-l.PEEP ventilation (TV of 10 ml/IBW and PEEP of 4 cm H2O)
Number of subjects: 24
Study 34348666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohort
Number of subjects: 24
Study 32364805 — intervention group
Group type: EXPERIMENTAL
Intervention: ER/DS mask (n=15)
Number of subjects: 31
Study 32364805 — intervention group
Group type: COMPARATOR
Intervention: Sham mask (n=16)
Number of subjects: 31
Study 32350847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin (180 mg/day)
Number of subjects: 26
Study 32350847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 32350847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 26
Study 34957008 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab combination therapy
Number of subjects: 0
Study 34957008 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 35409827 — intervention group
Group type: EXPERIMENTAL
Intervention: WeActive (aerobic and resistance training)
Number of subjects: 55
Study 35409827 — intervention group
Group type: EXPERIMENTAL
Intervention: WeMindful (mindful exercise)
Number of subjects: 55
Study 33958436 — intervention group
Group type: EXPERIMENTAL
Intervention: FACE‐TC (Advance Care Planning Survey; Next Steps: Respecting Choices; Five Wishes)
Number of subjects: 126
Study 33958436 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 126
Study 33261710 — intervention group
Group type: EXPERIMENTAL
Intervention: Livestock-transfer programs
Number of subjects: 78
Study 33261710 — intervention group
Group type: EXPERIMENTAL
Intervention: Leveraging livestock products for nutrition
Number of subjects: 78
Study 33261710 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping farmers manage priority diseases
Number of subjects: 78
Study 33261710 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease control interventions
Number of subjects: 78
Study 33261710 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions related to livestock production
Number of subjects: 78
Study 34641706 — intervention group
Group type: EXPERIMENTAL
Intervention: PZL (50 μg)
Number of subjects: 12
Study 34641706 — intervention group
Group type: EXPERIMENTAL
Intervention: LT3 (50 μg)
Number of subjects: 12
Study 34641706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 12
Study 33864342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh placement at the primary operation
Number of subjects: 0
Study 33864342 — intervention group
Group type: COMPARATOR
Intervention: Differing surgical techniques
Number of subjects: 0
Study 34076067 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of CBD powder
Number of subjects: 45
Study 34076067 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of CBD dissolved in corn oil
Number of subjects: 45
Study 34076067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 32795623 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility intervention group
Number of subjects: 20
Study 32795623 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength intervention group
Number of subjects: 20
Study 32740218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with or without vitamin K2 or vitamin K antagonists
Number of subjects: 0
Study 32740218 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 0
Study 32740218 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose apixaban (5 mg twice daily)
Number of subjects: 0
Study 32740218 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose apixaban (2.5 mg twice daily)
Number of subjects: 0
Study 32740218 — intervention group
Group type: COMPARATOR
Intervention: Apixaban initiation
Number of subjects: 0
Study 34559269 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA-soaked nasal packing
Number of subjects: 104
Study 34559269 — intervention group
Group type: COMPARATOR
Intervention: Saline-impregnated dressing
Number of subjects: 104
Study 32781931 — intervention group
Group type: EXPERIMENTAL
Intervention: Males (n=122)
Number of subjects: 305
Study 32781931 — intervention group
Group type: EXPERIMENTAL
Intervention: Females (n=183)
Number of subjects: 305
Study 32781931 — intervention group
Group type: EXPERIMENTAL
Intervention: General anxiety and number of cancer symptoms (both genders)
Number of subjects: 305
Study 32781931 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 305
Study 32781931 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 305
Study 34452927 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-7 (CYT107)
Number of subjects: 54
Study 34452927 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 54
Study 32739704 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) 3x/week for 6 weeks
Number of subjects: 42
Study 32739704 — intervention group
Group type: COMPARATOR
Intervention: Basic stretching activities (control) 3x/week for 6 weeks
Number of subjects: 42
Study 36352294 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS intervention
Number of subjects: 61
Study 33590823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (5 mg and 10 mg)
Number of subjects: 0
Study 33590823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33590823 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 0
Study 36041668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 36041668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 34454953 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) treatment
Number of subjects: 220
Study 34454953 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 220
Study 35439033 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (SXC) - 3 capsules (0.5 g/capsule) taken 3 times a day for 8 weeks
Number of subjects: 0
Study 35439033 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 0
Study 35051939 — intervention group
Group type: EXPERIMENTAL
Intervention: GCMO (internet-based self-help intervention)
Number of subjects: 351
Study 35051939 — intervention group
Group type: COMPARATOR
Intervention: MHA-W (mental health advice waiting group)
Number of subjects: 351
Study 33037801 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg)
Number of subjects: 30
Study 33037801 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg)
Number of subjects: 30
Study 33125454 — intervention group
Group type: EXPERIMENTAL
Intervention: CERC‐501 (10 mg/d for 6 days)
Number of subjects: 8
Study 33125454 — intervention group
Group type: EXPERIMENTAL
Intervention: CERC‐501 (20 mg/d for 6 days)
Number of subjects: 8
Study 33125454 — intervention group
Group type: EXPERIMENTAL
Intervention: CERC‐501 (10 mg/d for 3 days after placebo for 3 days)
Number of subjects: 8
Study 33125454 — intervention group
Group type: EXPERIMENTAL
Intervention: CERC‐501 (20 mg/d for 3 days after placebo for 3 days)
Number of subjects: 8
Study 33125454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 days)
Number of subjects: 8
Study 35420362 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg daily
Number of subjects: 150
Study 35420362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 34622768 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopur liquid (450 IU, 600 IU/0.96 mL)
Number of subjects: 76
Study 34622768 — intervention group
Group type: COMPARATOR
Intervention: Menopur powder (450 IU, by 2 subcutaneous injections of 225 IU in 1 mL)
Number of subjects: 76
Study 34622768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 76
Study 32776611 — intervention group
Group type: EXPERIMENTAL
Intervention: bretylium tosylate (10 mm)
Number of subjects: 20
Study 32776611 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 20
Study 35849181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based supportive psychotherapy (SP) for 6 sessions of 90-min
Number of subjects: 30
Study 35849181 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study 34358701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (70 mg or 210 mg every 4 weeks or 280 mg every 2 weeks)
Number of subjects: 550
Study 34358701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 33723662 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 15
Study 33723662 — intervention group
Group type: COMPARATOR
Intervention: Xenogeneic Dermal Matrix (XDM)
Number of subjects: 15
Study 32005777 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐DPA‐714 PET
Number of subjects: 37
Study 34245243 — intervention group
Group type: COMPARATOR
Intervention: IIV4
Number of subjects: 727
Study 32497489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Tranexamic Acid (DT) group
Number of subjects: 36
Study 32497489 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DS) group
Number of subjects: 36
Study 35683351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hzVSF-v13
Number of subjects: 64
Study 35683351 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hzVSF-v13
Number of subjects: 64
Study 35683351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33206670 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided recreational team handball training (THG) for 12 weeks, 1.8 times/week
Number of subjects: 54
Study 36163874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 250
Study 36163874 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus Rituximab (BR)
Number of subjects: 250
Study 34579783 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Self-management Support Programme (P-SUP) for 18 months
Number of subjects: 0
Study 34579783 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting control group)
Number of subjects: 0
Study 32907828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone (DH) closed-loop control
Number of subjects: 23
Study 32907828 — intervention group
Group type: COMPARATOR
Intervention: Insulin-only single-hormone (SH) closed-loop control
Number of subjects: 23
Study 32907828 — intervention group
Group type: COMPARATOR
Intervention: Predictive low glucose suspend (PLGS) system
Number of subjects: 23
Study 34632845 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized, multimodal weaning strategy implemented by a multidisciplinary care team
Number of subjects: 0
Study 34656197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-only psychotherapy (n = 21)
Number of subjects: 42
Study 34656197 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-only psychotherapy (n = 21)
Number of subjects: 42
Study 32800913 — intervention group
Group type: EXPERIMENTAL
Intervention: K levels ≥4.5 mEq/L within 36-56 hours prior to AKI diagnosis
Number of subjects: 430
Study 32800913 — intervention group
Group type: EXPERIMENTAL
Intervention: K levels in AKI group
Number of subjects: 430
Study 32800913 — intervention group
Group type: EXPERIMENTAL
Intervention: K levels in STEMI patients
Number of subjects: 430
Study 32800913 — intervention group
Group type: EXPERIMENTAL
Intervention: K levels in NSTEMI patients
Number of subjects: 430
Study 32800913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AKI)
Number of subjects: 430
Study 34931749 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (600 mg/d)
Number of subjects: 113
Study 34931749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 33206126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-care intervention (home visit within 7 days of discharge and twice-monthly telephone coaching for 3 months)
Number of subjects: 479
Study 33206126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-care intervention
Number of subjects: 479
Study 33206126 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 479
Study 35598594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated 5-aminolevulinic acid 20% (ALA)-PDT
Number of subjects: 162
Study 35598594 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-stage methyl aminolevulinate (MAL)-PDT
Number of subjects: 162
Study 35598594 — intervention group
Group type: COMPARATOR
Intervention: MAL-PDT
Number of subjects: 162
Study 35598594 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 162
Study 34175716 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise three times a week for 12 weeks
Number of subjects: 64
Study 34175716 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 64
Study 32060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation at 0, 750, 1,500, or 3,000 FTU/kg diet (Exp. 1)
Number of subjects: 8
Study 32060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation at 0 or 1,500 FTU/kg diet (Exp. 2)
Number of subjects: 8
Study 32060531 — intervention group
Group type: COMPARATOR
Intervention: No phytase supplementation (Control)
Number of subjects: 8
Study 32060531 — intervention group
Group type: COMPARATOR
Intervention: RSC diet (Control)
Number of subjects: 8
Study 32060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation
Number of subjects: 8
Study 32060531 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase supplementation
Number of subjects: 8
Study 34062004 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor plus bortezomib-dexamethasone (XVd)
Number of subjects: 402
Study 34062004 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib-dexamethasone (Vd)
Number of subjects: 402
Study 33044213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment via ear canals
Number of subjects: 27
Study 33290538 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 140
Study 33290538 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 10 mg BID
Number of subjects: 140
Study 32393129 — intervention group
Group type: EXPERIMENTAL
Intervention: Copayment assistance voucher intervention
Number of subjects: 10102
Study 32393129 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no voucher)
Number of subjects: 10102
Study 35514035 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean hulls low‐fibre (SHL, 6.00% crude fibre)
Number of subjects: 40
Study 35514035 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean hulls high‐fibre (SHH, 8.00% crude fibre)
Number of subjects: 40
Study 35514035 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn stalk high‐fibre (CSH, 8.00% crude fibre)
Number of subjects: 40
Study 35514035 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn stalk low‐fibre (CSL, 6.00% crude fibre)
Number of subjects: 40
Study 35514035 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, 3.15% crude fibre)
Number of subjects: 40
Study 33270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative C-reactive protein (pre-CRP) ≥3.1 mg/L (high-pre-CRP)
Number of subjects: 401
Study 33270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative maximum C-reactive protein (post-CRPmax) ≥77.1 mg/L (high-post-CRPmax)
Number of subjects: 401
Study 33270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (ACT)
Number of subjects: 401
Study 33270989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CRP <3.1 mg/L
Number of subjects: 401
Study 32446675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Learning
Number of subjects: 146
Study 32446675 — intervention group
Group type: COMPARATOR
Intervention: See One, Do One
Number of subjects: 146
Study 35811226 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrates (POC) intake in Fpo and Spo groups
Number of subjects: 200
Study 35811226 — intervention group
Group type: COMPARATOR
Intervention: Control group (F and S groups without carbohydrates)
Number of subjects: 200
Study 35811226 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Fpo, Spo, F, and S)
Number of subjects: 200
Study 33847366 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in guideline-oriented biopsychosocial management of LBP (3-7 days training)
Number of subjects: 234
Study 33847366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 234
Study 35819352 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 14
Study 35819352 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 14
Study 32575387 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole almonds
Number of subjects: 105
Study 32575387 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control snacks
Number of subjects: 105
Study 36177001 — intervention group
Group type: EXPERIMENTAL
Intervention: High autophagy status and high immune status
Number of subjects: 0
Study 36177001 — intervention group
Group type: EXPERIMENTAL
Intervention: Autophagy-immune-related prognostic risk model
Number of subjects: 0
Study 36177001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 0
Study 36177001 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 0
Study 34475473 — intervention group
Group type: EXPERIMENTAL
Intervention: T3-T4 sympathicotomy
Number of subjects: 42
Study 34475473 — intervention group
Group type: COMPARATOR
Intervention: T3-T4 gray ramicotomy
Number of subjects: 42
Study 34780798 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg/mL rhNGF eye drops, 3 times daily for 8 weeks
Number of subjects: 60
Study 34780798 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control eye drops
Number of subjects: 60
Study 34780798 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg/mL rhNGF eye drops
Number of subjects: 60
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in low-risk group
Number of subjects: 1078
Study 33930541 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in variable-risk group
Number of subjects: 1078